Kingston, Canada Clinical Trials

A listing of Kingston, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 154 clinical trials
featured
Fox Insight - Online Parkinson's Health and Genetic Study

Fox Insight is an online study gathering health information from tens of thousands of people with and without Parkinson’s disease.  Study participation does not require any travel and all you need is an internet connection to start today at www.foxinsight.org Fox Insight volunteers are invited to take part in virtual …

www.foxinsight.org
 (8.8 away) Contact site
  • 3557 views
  • 29 Mar, 2021
  • +333 other locations
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require …

Ottawa Hospital Research Institute
 (88.2 away) Contact site
  • 41 views
  • 26 Jan, 2021
  • +97 other locations
SAHaRA: A Randomized Controlled Trial

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Shane English
 (88.2 away) Contact site
  • 173 views
  • 25 Jan, 2021
  • +14 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

cancer
x-rays
oropharyngeal carcinoma
treatment schedule
human papillomavirus
Kingston Health Sciences Centre
 (0.6 away) Contact site
  • 56 views
  • 21 Jul, 2021
  • +29 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

cancer
pd-l1
metastasis
progressive disease
biomarker analysis
Kingston Health Sciences Centre ( Site 1503)
 (0.6 away) Contact site
  • 122 views
  • 23 Jul, 2021
  • +149 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Kingston Health Sciences Centre -- Hotel Dieu Hospital
 (0.0 away) Contact site
  • 10 views
  • 07 Jul, 2021
  • +216 other locations
Study Looking at Biomarkers in Ovarian Cancer

This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide …

ovarian cancer
cancer
Kingston Health Sciences Centre
 (0.6 away) Contact site
  • 20 views
  • 20 Apr, 2021
  • +4 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)
 (0.6 away) Contact site
  • 0 views
  • 05 Jul, 2021
  • +397 other locations
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

lung carcinoma
cancer chemotherapy
durvalumab
Research Site
 (0.6 away) Contact site
  • 102 views
  • 21 Jul, 2021
  • +245 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (0.6 away) Contact site
  • 50 views
  • 11 Jul, 2021
  • +223 other locations